Evidence map›Paper›PMID 30759116›Full record

ArticlePloS one2019

Analytical characterization and reference interval of an enzyme-linked immunosorbent assay for active von Willebrand factor.

Lisa N van der Vorm, Li Li, Dana Huskens, Walid Chayouâ, Hilde Kelchtermans, Philip G de Groot, Mark Roest, Jasper A Remijn, Bas de Laat

Open access · goldAbstract readValidation Study
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. VWF, Platelets and the Antiphospholipid Syndrome.International journal of molecular sciences · 2021
    Review
  9. Observational
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Lisa N van der VormCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.ORCID 0000-0003-0698-5878
Li LiCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Dana HuskensCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.ORCID 0000-0002-5999-5685
Walid ChayouâCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Hilde KelchtermansCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Philip G de GrootCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Mark RoestCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Jasper A RemijnCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Bas de LaatCardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, The Netherlands.
Maastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInteraction of von Willebrand factor (VWF) with platelets requires a conformational change that exposes an epitope within the VWF A1 domain, enabling platelet glycoprotein Ibα binding. Quantification of this ''active" conformation of VWF has been shown to provide pathophysiological insight into conditions characterized by excessive VWF-platelet interaction.

methodsWe developed an immunosorbent assay based on a variable heavy chain antibody fragment against the VWF A1 domain as a capture antibody. Assay performance in terms of specificity (binding to active R1306W- and sheared VWF), precision, accuracy, linearity, limits of detection and stability were determined. Active VWF, VWF antigen, VWF ristocetin cofactor activity, VWF:GP1bM and VWF propeptide were measured in citrated plasma and platelet-VWF binding in whole blood from 120 healthy individuals to establish a reference interval for active VWF and to assess associations with other VWF parameters.

resultsIntra- and inter-assay CVs were between 2.4-7.2% and 4.1-9.4%, depending on the level. Mean recovery of spiked recombinant R1306W VWF was 103±3%. The assay was linear in the range of 90.1-424.5% and had a limit of quantification of 101%. The reference interval for active VWF was 91.6-154.8% of NPP. Significant, positive correlations between active VWF and all other VWF parameters were found, with the strongest correlation with VWF:GP1bM binding.

conclusionsWe developed and validated an immunosorbent assay for the accurate detection of active VWF levels in plasma. The assay fulfilled all analytical criteria in this study and a reference interval was established, allowing its use to quantify active VWF in pathological conditions for future research.

Indexed as

AdolescentAdultAgedAntibodiesBlood PlateletsEnzyme-Linked Immunosorbent AssayEpitopesFemaleHumansMaleMiddle AgedReference Valuesvon Willebrand Diseasesvon Willebrand FactorYoung AdultAntibodiesEpitopesvon Willebrand Factor

Identifiers

PMID30759116
PMCPMC6373957
OpenAlexW2912204111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.